Question explored with the scientific record
Is there an effective treatment for ms?
The short version: the evidence shows these drugs reduce relapses, but the trials were funded by the manufacturers and the long-term safety picture is incomplete.
The evidence you retrieved is almost entirely about relapsing-remitting MS, not progressive forms. The core finding across multiple manufacturer-funded trials is that drugs like fingolimod, natalizumab, and teriflunomide cut annual relapse rates roughly in half compared to placebo or older injectables [2, 5, 8, 10]. A 30-year Finnish cohort reported that people who ever took a disease-modifying therapy had a 93% survival rate versus 81% for the untreated [1]. That sounds dramatic, but it is an observational comparison, not a randomized trial, and the treated group may have been healthier or more engaged with care to begin with.
The safety data is thin for the long term. The newest drug in this set, ofatumumab, has up to six years of follow-up showing mostly mild infections and a 1.3% malignancy rate [7]. But the trials compared ofatumumab to teriflunomide, not to no treatment, so the net benefit over doing nothing is inferred, not directly measured. Fingolimod causes lymphopenia in 27% of patients and liver enzyme elevations in 29% [8]. Teriflunomide causes hair thinning in 13% and liver enzyme increases in 14% [10]. These are real trade-offs.
| Drug | Relapse reduction vs placebo | Key adverse events |
|---|---|---|
| Fingolimod 0.5 mg | 52% lower annual relapse rate [8] | Lymphopenia 27%, liver enzymes 29%, hypertension 32% [8] |
| Teriflunomide 14 mg | 36% lower annual relapse rate [10] | Hair thinning 13%, liver enzymes 14% [10] |
| Natalizumab | 0.159 vs 0.507 relapses per year [1] | Not detailed in this evidence |
My call: for someone with active relapsing-remitting MS, these drugs probably reduce relapses, but the evidence base is funded by the manufacturers and long-term safety beyond six years is not established. Confidence: moderate for relapse reduction, low for long-term safety.
Sources used 25
-
A Restrospective Non-Interventional Study Among Patients with Relapsing Multiple Sclerosis Switching to Fingolimod or to Other Disease Modifying Therapies
A compilation of real-world observational studies across multiple countries evaluating relapse rates, symptom management, and survival in relapsing multiple sclerosis, comparing natalizumab and other disease-modifying therapies, including therapy switches and long-term outcomes,…
DOI: 10.1016/j.jval.2016.09.465 -
Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis
This study conducted a network meta-analysis of disease-modifying therapies for relapsing-remitting multiple sclerosis, finding that alemtuzumab, natalizumab, and ocrelizumab are the most effective treatments based on annualized relapse rates.
DOI: 10.1007/s40263-018-0541-5 -
Treatment with interferon beta-1a in brazil is associated with fewer hospitalizations due to relapse, better adherence and a better response compared to other platform therapies
This study assesses compliance and discontinuation rates of disease-modifying therapies (DMTs) in Canadian patients with relapsing-remitting multiple sclerosis (RRMS), revealing that fingolimod has the highest compliance and lowest discontinuation rates compared to other DMTs.
DOI: 10.1016/j.jval.2016.03.234 -
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)
This study analyzes the efficacy and safety of fingolimod compared to interferon β-1a intramuscular in patients with relapsing multiple sclerosis, focusing on the impact of prior treatment status and reasons for discontinuation.
DOI: 10.1016/j.msard.2013.11.006 -
Fingolimod: new oral treatment for relapsing‐remitting MS
This study evaluates the efficacy and safety of fingolimod as a disease-modifying therapy for adults with relapsing-remitting multiple sclerosis (RRMS), demonstrating significant reductions in relapse rates and disability progression compared to placebo and interferon beta-1a.
DOI: 10.1002/psb.859 -
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study
This study analyzes the efficacy and safety of fingolimod in patients with relapsing multiple sclerosis, focusing on subgroups defined by prior treatment history and reasons for discontinuation, revealing significant reductions in annualized relapse rates across various patient …
DOI: 10.1016/j.msard.2013.10.006 -
The long-term safety of ofatumumab in multiple sclerosis
Subcutaneous ofatumumab shows a favorable long-term safety profile in relapsing multiple sclerosis, with mainly mild infections, a very low neutropenia risk, transient but non‑concerning IgM/IgG declines, and a low malignancy rate over up to six years.
DOI: 10.15557/an.2025.0019 -
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
The FREEDOMS II trial demonstrated that fingolimod significantly reduces annualized relapse rates and brain volume loss in patients with relapsing-remitting multiple sclerosis, although it did not show a significant effect on disability progression.
DOI: 10.1016/S1474-4422(14)70049-3 -
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
This study investigates the dynamics of SARS-CoV-2 infections and vaccinations in a large cohort of people with multiple sclerosis (pwMS) in Germany, revealing significant associations between demographic and disease-related factors and vaccination/infection rates.
DOI: 10.3390/vaccines12030265 -
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
The TOWER trial demonstrated that oral teriflunomide significantly reduces the annualized relapse rate and the risk of disability accumulation in patients with relapsing multiple sclerosis compared to placebo.
DOI: 10.1016/s1474-4422(13)70308-9 -
Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis
This study investigates the long-term effects of pregnancy on disability progression in women with multiple sclerosis, finding that parity is associated with a longer time to reach significant disability milestones.
DOI: 10.1177/1352458514561907 -
Disease Steps in multiple sclerosis
This study introduces the Disease Steps scale as a simple and reproducible method for assessing disability in multiple sclerosis (MS), demonstrating its effectiveness compared to the Expanded Disability Status Scale (EDSS) in categorizing patients and measuring disease progressi…
DOI: 10.1212/WNL.45.2.251 -
Gray matter atrophy in multiple sclerosis: A longitudinal study
This longitudinal study investigates gray matter atrophy rates in multiple sclerosis patients across different disease stages, revealing that gray matter damage significantly correlates with disability and varies between relapsing-remitting and secondary progressive forms of the…
DOI: 10.1002/ana.21436 -
Defining the natural history of MS: the need for complete data and rigorous definitions
This study critiques the methodology and findings of a Canadian research group on the natural history of secondary progressive multiple sclerosis (SPMS), emphasizing the need for complete data and rigorous definitions in understanding disease progression.
DOI: 10.1177/1352458508088625 -
Timing of birth and disease progression in multiple sclerosis
This study investigates the influence of the timing of birth on disease progression in multiple sclerosis, finding no significant associations in two large cohorts from Europe and North America.
DOI: 10.1177/1352458508090662 -
Aggressive multiple sclerosis: proposed definition and treatment algorithm
This paper proposes a definition and treatment algorithm for aggressive multiple sclerosis (MS), emphasizing the need for early identification and intervention to prevent irreversible disability.
DOI: 10.1038/nrneurol.2015.85 -
Longitudinal follow-up of “benign” multiple sclerosis at 20 years
This study evaluates the long-term disease status of patients initially classified as having 'benign' multiple sclerosis after 20 years, revealing significant progression in disability and questioning the adequacy of current definitions of benign MS.
DOI: 10.1212/01.wnl.0000253185.03943.66 -
Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium
This study analyzes the New York State Multiple Sclerosis Consortium registry to compare African American and non-African American MS patients, finding African American patients have greater disability with longer disease duration, earlier diagnosis for some groups, and potentia…
DOI: 10.1191/1352458503ms909oa -
Influence of treatments in multiple sclerosis disability: A cohort study
This cohort study investigates the impact of disease-modifying drugs on long-term disability progression in multiple sclerosis patients, revealing that treatments significantly reduce the risk of reaching disability milestones compared to untreated patients.
DOI: 10.1177/1352458514546788 -
Epilepsy in multiple sclerosis
This study investigates the cumulative incidence of epilepsy in a population-based cohort of patients with multiple sclerosis (MS) and finds that MS significantly increases the risk of developing epilepsy, particularly in patients with progressive disease and higher disability s…
DOI: 10.1212/wnl.0000000000004740 -
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
In multiple sclerosis patients who were relapse-free for at least 5 years on injectable disease-modifying therapy, stopping treatment did not increase relapse risk compared with propensity-score matched stayers but significantly increased the hazard of disability progression, es…
DOI: 10.1136/jnnp-2016-313760 -
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
This study evaluates the efficacy and safety of induction therapy with mitoxantrone followed by maintenance therapy in patients with aggressive forms of multiple sclerosis, demonstrating significant reductions in disease activity and disability progression over a long-term follo…
DOI: 10.1007/s40263-013-0065-y -
A systematic review of factors associated with accidental falls in people with multiple sclerosis: a meta-analytic approach
A comprehensive meta-analysis of 15 studies (n = 2,425 people with multiple sclerosis) identifies longer disease duration, progressive disease course, greater disability, slower walking speed, poorer balance, and use of walking aids as key factors associated with higher fall ris…
DOI: 10.1177/0269215513517575 -
Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
The authors propose a four-domain, evidence-based metric (the Multiple Sclerosis Decision Model, MSDM) to monitor disease activity and guide early treatment changes in multiple sclerosis by integrating relapses, disability progression, MRI activity, and neuropsychology into a pr…
DOI: 10.1177/1756285614560733 -
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis
This prospective study quantifies how much methylprednisolone from IV pulse therapy for multiple sclerosis relapses transfers into human milk during breastfeeding and finds very low infant exposure (RID ~0.71%), with no observed short-term infant adverse effects, supporting safe…
DOI: 10.1177/1352458517717806